Environmental biotechnology is the branch of biotechnology that addresses environmental problems, such as the removal of pollution, renewable energy generation or biomass production, by exploiting ...

Fabio Campanile, global head of Science & Technology, Taste & Wellbeing at Givaudan, said, “As a global leader in flavours, taste, functional and nutritional solutions, with deep expertise in biotech, ...

Windlas Biotech announced that it has received Good Manufacturing Practices (GMP) certification for its new State-of-the-Art Injectable facility from the Food Safety & Drugs Administration Authority ...

Commissions do not affect our editors' opinions or evaluations. Biotech stocks are not for the faint of heart. These highly volatile equities can see stomach-churning price swings, driven by how ...

Clip-on aerobars, which are also known as triathlon bars, are handlebar extensions with padded forearm rests that allow the rider to get into a more aerodynamic position by drawing their body forward ...

In 2024, Fierce Biotech reported 192 industry layoff rounds, which is 3% higher than in 2023, when 187 rounds were tallied. Rounds are reported as they are disclosed and are not combined per ...

Re­gen­eron, mak­er of the block­buster oph­thal­mol­o­gy med­i­cine Eylea, has ac­quired an oc­u­lar biotech, the large bio­phar­ma con­firmed to End­points News on Thurs­day.

No Oxular employees are joining Regeneron, though several will be “helping short-term with tech transfer and transition work in consulting roles,” a Regeneron spokesperson told Fierce Biotech ...

2024 was the year of the pri­vate megaround. Nine-fig­ure fi­nanc­ings dom­i­nat­ed biotech’s ven­ture fund­ing land­scape, with 96 such rounds tal­lied by End­points News. The bevy … ...

Carmell acquires Elevai Skincare, adding $2.5M in annual revenue and advanced exosome technology to its portfolio. Deal includes $1.1M in equity, $57K in cash, and earnouts tied to sales and ...

The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies have slowed. An anticipated upswing in initial public offerings hasn’t ...